NextBio

Help
Description: Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
Drug Type: Small Molecule; Approved
Pharmacology: Vinblastine is a vinca alkaloid antineoplastic agent. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units: vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vinblastine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.
Mechanism of Action: The antitumor activity of vinblastine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Vinblastine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death.
Indication: For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.
Half Life: Triphasic: 35 min, 53 min, and 19 hours
View Complete Description



Data Correlations | 6 studies

Help for Data Correlations View All
Genes category icon Genes
Score Help
TUBB2C 100 100
STAC3 90 90
LCN2 83 83
ALAS2 79 79
CCL20 79 79
GUCY2C 78 78
View Top Genes
Biogroups category icon Biogroups
Score Help
Beta tubulin, autoregulation bindin… 100 100
GAP Junction 100 100
Tubulin Protein Family 100 100
Sulphotransferase 93 93
RNA-directed DNA polymerase (revers… 92 92
Beta-Oxidation of Fatty Acids 92 92
View Top Biogroups

Individual Studies

  • Vincristine resistant or sensitive human ovarian cancer cells

    Homo sapiens Homo sapiens | RNA Expression   RNA Expression

    Gene expression profiles were assessed for vincristine-sensitive parental ovarian tumor cell line (SKOV3) and its highly vincristine-resistant derivative (SKVCR 2.0)

    Authors: Buys P Timon, Chari Raj, Lee H Eric et al.

    Organization: British Columbia Cancer Research Centre …

  • Drug target sets for approved compounds

    Homo sapiens Homo sapiens | Therapeutic   Therapeutic

    The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

    Authors: David S Wishart, Craig Knox, An Chi Guo et al.

    Organization: Department of Computing Science, Univers…
View All Individual Studies

Associated Researchers

Help for Associated Researchers

Thought leaders and organizations working on research involving Vinrosidine.

View All Author iconAuthors
  • Timothy C Chambers
  • Meenakshi Upreti
  • Satoshi Yokoshima
  • Hayato Ishikawa
  • Danilo Marimpietri
View All Clinical trial sponsors icon Clinical Trials Sponsors
  • M.D. Anderson Cancer Center
  • Children's Oncology Group
  • University of Cologne
  • The Hospital for Sick Children
  • Southwest Oncology Group
View All Affiliations icon Organizations
  • University of Arkansas for Medical Sciences
  • University of Bari Medical School
  • University of Tokyo
  • Scripps Research Institute
  • Centre National de la Recherche Scientifique

Clinical Trials | 180 trials

Help for Clinical Trials View All

Community

Help for Community
NextBio Users

  • No NextBio users were found for “Vinrosidine”.
    Complete your user profile with your interests, if you want others to find you within the NextBio community.

NextBio Groups

  • No NextBio groups were found for “Vinrosidine”.
    Be the first to start a group and share your interests with others within the NextBio community.

© 2010 NextBio